AbbVie Strengthens Immunology Leadership with $10.9 Billion Apogee Therapeutics Acquisition – Meet them this November

Talawar Therapeutics Heads to Nasdaq via SPAC Deal to Bankroll Eczema Asset

10 Clinical Trials to Watch Out for in the latter half of 2026 – Read here

Akero execs reunite to advance long-acting psoriasis pill

Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug

InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test

Sanofi halts development of troubled immune drug in eczema

Moving Beyond Single-Target Therapies: Clinical Development Insights from a Multi-Target Platform in Atopic Dermatitis & Molluscum Contagiosum

11:30 am - Wednesday 4th November 2026

Exploring how multi-mechanistic therapeutics may address complex disease biology more effectively than conventional single-target approaches
Reviewing pharmacokinetic, mechanistic and translational learnings supporting development across inflammatory and infectious dermatological conditions
Discussing Phase 2 clinical development strategies and crossindication insights to accelerate future applications of multitarget therapeutics

Neal Koller

Chairman of Directors & Chief Executive Officer

Alphyn Biologics